CareDx agrees to sell lab products unit to EuroBio Scientific for $170 million
PUBT · 23h ago
Share
Listen to the news
- CareDx agreed to sell its Lab Products business to EuroBio Scientific for USD 170 million in cash at closing.
- Deal includes in vitro diagnostic PCR and NGS transplant-typing kits, plus NGS-based monitoring assays sold outside North America.
- EuroBio granted CareDx sole, perpetual rights to distribute post-transplant monitoring IVD tests in North America, including AlloSeq cfDNA.
- Closing targeted by end of CareDx third quarter 2026, subject to Swedish regulatory review tied to sale of CareDx Swedish entity.
- CareDx expects to provide transition services for at least six months at EuroBio expense.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CareDx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260415770733) on April 15, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved